Safety Evaluation of 3K3A-APC in Ischemic Stroke
Public ClinicalTrials.gov record NCT02222714. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Phase 2 Study Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC in Combination With tPA, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of multiple ascending intravenous doses of 3K3A-APC, a Recombinant Variant of Human activated protein C (APC), in in the treatment of acute ischemic stroke following treatment with recombinant tissue plasminogen activator (tPA), mechanical thrombectomy or both.
Study identification
- NCT ID
- NCT02222714
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 110 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2014 (Type not available)
- Primary completion
- Apr 18, 2017 (Actual)
- Completion
- Jun 29, 2017 (Actual)
- Last update posted
- Nov 8, 2018
2014 – 2017
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stroke Center | Los Angeles | California | 90048 | — |
| Stroke Center | Chicago | Illinois | 60611 | — |
| Stroke Center | Kansas City | Kansas | 66160 | — |
| Stroke Center | Boston | Massachusetts | 02114 | — |
| Stroke Center | St Louis | Missouri | 63110 | — |
| Stroke Center | Buffalo | New York | 14209 | — |
| Stroke Center | New York | New York | 10032 | — |
| Stroke Center | Rochester | New York | 14642 | — |
| Stroke Center | Cincinnati | Ohio | 45208 | — |
| Stroke Center | Columbus | Ohio | 43210 | — |
| Stroke Center | Pittsburgh | Pennsylvania | 15213 | — |
| Stroke Center | Nashville | Tennessee | 37232 | — |
| Stroke Center | Dallas | Texas | 75390 | — |
| Stroke Center | Salt Lake City | Utah | 84132 | — |
| Stroke Center | Charlottesville | Virginia | 22904 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02222714, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02222714 live on ClinicalTrials.gov.